United States Chronic Kidney Disease Drugs Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Global Chronic Kidney Disease Drugs Market was valued at US$ 10,923.29 million in 2021 and is estimated to reach US$ 19,427.41 million by 2031, growing at a CAGR of 6.6% during the forecast period 2024-2031.

Key Development:

United States: Recent Industry Developments

✅ July 2025: Bayer announced that KERENDIA® (finerenone) received expanded approval to reduce the risk of cardiovascular death, hospitalization for heart failure, non-fatal myocardial infarction, sustained eGFR decline, and end-stage kidney disease in adults with chronic kidney disease associated with type 2 diabetes.

✅ March 2025: The FDA approved Fabhalta (iptacopan) for adults with complement 3 glomerulopathy (C3G) to reduce proteinuria, offering a breakthrough therapy for this rare and serious kidney disorder.

✅ January 2025: The FDA approved Ozempic (semaglutide) for adults with type 2 diabetes and chronic kidney disease, marking the first GLP-1 receptor agonist approved for this indication to reduce kidney failure risk and cardiovascular complications.

Japan: Recent Industry Developments

✅ August 2024: Pathalys Pharma raised $105 million in Series B funding to advance its leading candidate upacicalcet through late-stage clinical development, aimed at improving treatment for secondary hyperparathyroidism in hemodialysis patients.

✅ August 2021: AstraZeneca's Forxiga (dapagliflozin) was approved in Japan for treating chronic kidney disease in adults, with or without type 2 diabetes, broadening its clinical use for renal protection.

✅ July 2020: Otsuka Pharmaceutical launched NephU, an online healthcare community dedicated to kidney health, designed to support healthcare professionals and patients through education and collaborative resources.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/chronic-kidney-disease-drugs-market?sb

Chronic kidney disease (CKD) drugs are medications designed to slow disease progression, manage symptoms, and reduce complications associated with declining kidney function. These include ACE inhibitors, ARBs, SGLT2 inhibitors, and phosphate binders, aiming to improve renal outcomes and enhance patients' quality of life.

Recent Mergers and acquisitions:

United States: Recent M&A and Partnerships

✅ September 2025: Arch Biopartners acquired Lipidro Therapeutics, gaining access to a pre-clinical platform targeting interleukin-32 (IL-32). The deal strengthens Arch's pipeline for developing next-generation drugs aimed at treating chronic kidney disease.

✅ August 2025: MannKind Corporation announced the acquisition of scPharmaceuticals, enhancing its portfolio in cardiorenal medicine. The move expands MannKind's footprint in CKD management through FUROSCIX, a therapy for fluid overload in heart failure and kidney disease patients.

✅ Recent (2023-2024): Kyowa Hakko Kirin entered into a licensing agreement with Reata Pharmaceuticals for the late-stage CKD drug bardoxolone methyl. The deal grants Kyowa exclusive rights for Japan and parts of Asia, while Reata retains global rights elsewhere.

✅ Recent (2023): Amgen completed the acquisition of KAI Pharmaceuticals for approximately $315 million. The acquisition adds KAI's experimental therapy, KAI-4169, for secondary hyperparathyroidism in dialysis patients to Amgen's nephrology portfolio.

Japan / Asia: Recent M&A and Partnerships

✅ February 2025: Bain Capital completed the acquisition of Mitsubishi Tanabe Pharma for approximately ¥510 billion (US $3.3 billion). The deal provides Mitsubishi Tanabe with greater flexibility and resources to accelerate innovation in kidney and metabolic disease drug development.

✅ 2024: Renalys Pharma secured ¥6.0 billion in Series A financing, co-led by Catalys Pacific and SR One, to advance sparsentan for IgA nephropathy and expand kidney disease treatment options across Asia.

✅ Recent (Ongoing Collaboration): Akebia Therapeutics partnered with Mitsubishi Tanabe Pharma to develop and commercialize vadadustat for the treatment of CKD-related anemia in Japan and Asian markets. The collaboration includes shared development costs and milestone-based payments.

Key Players:

=> Sanofi S.A., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., AstraZeneca Plc., Kissei Pharmaceutical Co, AbbVie Inc., GlaxoSmithKline Plc, Amgen Inc., Akebia Therapeutics and more.

Growth Forecast Projected:

The Global Chronic Kidney Disease Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Chronic Kidney Disease Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=chronic-kidney-disease-drugs-market

Key Segments:

➥ By Drug Class: ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Diuretics, Erythropoiesis-Stimulating Agents, Others
➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others

Regional Analysis for Chronic Kidney Disease Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Chronic Kidney Disease Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Chronic Kidney Disease Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/chronic-kidney-disease-drugs-market?sb

FAQ

What is the current size of the Chronic Kidney Disease Drugs Market?

A: In 2021, the Chronic Kidney Disease Drugs Market was valued at US$ 10,923.29 million, reflecting its strong industry presence.

Q2: How large is the Chronic Kidney Disease Drugs Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Chronic Kidney Disease Drugs Market will grow to around US$ 19,427.41 million, demonstrating significant expansion.

Q3: What is the growth rate of the Chronic Kidney Disease Drugs Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 6.6% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.